Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPARa/? Agonist Activity.

Autores de INCLIVA
Participantes ajenos a INCLIVA
- Garcia, A
- Marin, P
- Bernabeu, A
- Hennuyer, N
- Staels, B
- Franck, X
- Figadere, B
Grupos y Plataformas de I+D+i
Abstract
We have synthesized series of 2-prenylated benzopyrans as analogues of the natural polycerasoidol, a dual PPARa/? agonist with anti-inflammatory effects. The prenylated side chain consists of five or nine carbons with an a-alkoxy-a,ß-unsaturated ester moiety. Prenylation was introduced via the Grignard reaction, followed by Johnson-Claisen rearrangement, and the a-alkoxy-a,ß-unsaturated ester moiety was introduced by the Horner-Wadsworth-Emmons reaction. Synthetic derivatives showed high efficacy to activate both hPPARa and hPPAR? as dual PPARa/? agonists. These prenylated benzopyrans emerge as lead compounds potentially useful for preventing cardiometabolic diseases.
© 2021 American Chemical Society.
Datos de la publicación
- ISSN/ISSNe:
- 1948-5875, 1948-5875
- Tipo:
- Article
- Páginas:
- 1783-1786
- PubMed:
- 34795868
ACS Medicinal Chemistry Letters American Chemical Society
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Financiación
Proyectos y Estudios Clínicos
Synthesis and pharmacological evaluation of new dual PPARalpha/gamma agonists as new therapeutic tools in the control of cardiometabolic disorders
Investigador Principal: NURIA CABEDO ESCRIG
CP15/00150 . INSTITUTO SALUD CARLOS III . 2016
Desarrollo quimico y farmacologico de nuevos farmacos "multidiana" en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular asociada
Investigador Principal: NURIA CABEDO ESCRIG
PI18/01450 . INSTITUTO SALUD CARLOS III . 2019
FI19/00153 (PFIS) CARLOS VILLARROEL (209/207): CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD. Acción Estratégica en Salud 2019.
Investigador Principal: NURIA CABEDO ESCRIG
FI19/00153 . INSTITUTO SALUD CARLOS III
Desarrollo de nuevos fármacos “multidiana” en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular associada.
Investigador Principal: NURIA CABEDO ESCRIG
APOTIP/2020/011 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO
CONTRATOS MIGUEL SERVET TIPO II
Investigador Principal: NURIA CABEDO ESCRIG
CPII20/00010 . INSTITUTO SALUD CARLOS III